Current patients: Such a good experience
The advisory committee's recommendation is not binding, but historically the FDA adopts PCAC vote outcomes in its final 503A bulk substance determinations
Refer to the ADVERSE EVENTS PRECAUTIONS To minimize the risk of potential complications, this product should only be used by healthcare professionals who have appropriate training, experience, and who are knowledgeable about the anatomy at and around the site of injection Discuss all potential risks of soft tissue injections with patients prior to treatment and ensure patients are aware of signs and symptoms of potential complications Limit patients to 20 mL of any JUVDERM injectable gel per 60 kg (130 lbs.) body mass per year
Self-funded injections should only be considered after proper medical assessment, as underlying conditions requiring investigation may be missed
What Reclassification Would (and Would Not) Change If BPC-157 is moved to Category 1 after the July 2026 meeting, the regulatory impact is narrower than many online summaries suggest: Scenario Category 2 (current default) Category 1 (post-reclassification) FDA approval No No 503A compounding Not permitted Permitted (pending final rulemaking) 503B outsourcing facilities Separate list (503B bulks list) Separate determination required Commercial drug product Not available Still not available without NDA Research/laboratory use Legal for research Legal for research (unchanged) In plain terms: Category 1 status lets a patient with a valid prescription get BPC-157 prepared by a state-licensed compounding pharmacy
Limitations of Current Fat Loss Research While promising, research on AOD-9604 has limitations: Preclinical focus: Researchers base most findings on in vitro or animal models, with limited human data available
